✦ LIBER ✦

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors

✍ Scribed by Sicklick, Jason K.; Lopez, Nicole E.

Book ID: 120682314
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 571 KB
Volume: 17
Category: Article
ISSN: 1091-255X
DOI: 10.1007/s11605-013-2243-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant imatinib therapy for gastrointe

Adjuvant imatinib therapy for gastrointestinal stromal tumors

✍ Peter W.T. Pisters; Chiara Colombo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Surgical Resection of Gastrointestinal S

Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib

✍ Robert H. I. Andtbacka; Chaan S. Ng; Courtney L. Scaife; Janice N. Cormier; Kell 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 236 KB

Surgical intervention for imatinib and s

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

✍ Hirotoshi Kikuchi; Tomohiko Setoguchi; Shinichiro Miyazaki; Masayoshi Yamamoto; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 593 KB

Surgical interventions for focal progres

Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy

✍ Junichi Hasegawa; Tatsuo Kanda; Seiichi Hirota; Masafumi Fukuda; Akiko Nishitani 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 224 KB

Surgical treatment of gastrointestinal s

Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era

✍ Peter C Wu; Alex Langerman; Christopher W Ryan; John Hart; Susan Swiger; Mitchel 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 423 KB

Systemic therapy for advanced gastrointe

Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib

✍ Edward J. Kim; Mark M. Zalupski 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Abstract Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR